EcoDrugPlus

5-Hydroxytryptamine Receptor 1a-Beta

Ensembl ID : ENSSLUG00000022843
Gene Symbol: LOC116034825
3 Cross references
137 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSSLUG00000021787
Gene Symbol: HTR1B
1 Cross references
182 Possible Orthologues:

5-Hydroxytryptamine Receptor 1e

Ensembl ID : ENSSLUG00000009885
Gene Symbol: HTR1E
1 Cross references
146 Possible Orthologues:

5-Hydroxytryptamine Receptor 1f

Ensembl ID : ENSSLUG00000024745
Gene Symbol: HTR1F
3 Cross references
140 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSSLUG00000020383
Gene Symbol: HTR2A
3 Cross references
216 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSSLUG00000012772
Gene Symbol: HTR3A
1 Cross references
203 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSSLUG00000010737
Gene Symbol: HTR4
1 Cross references
198 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSSLUG00000018922
Gene Symbol: HTR5A
3 Cross references
209 Possible Orthologues:

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSSLUG00000005164
Gene Symbol: HTR7
1 Cross references
196 Possible Orthologues:

60s Ribosomal Protein L10

Ensembl ID : ENSSLUG00000015039
Gene Symbol: LOC116058161
3 Cross references
409 Possible Orthologues:

60s Ribosomal Protein L19-Like

Ensembl ID : ENSSLUG00000014966
Gene Symbol: LOC116061039
3 Cross references
328 Possible Orthologues:

60s Ribosomal Protein L22

Ensembl ID : ENSSLUG00000023240
Gene Symbol: LOC116058771
3 Cross references
208 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).